瑞舒伐他汀治疗相关的肾小管毒性
本文报告一例无既往肾脏疾病证据的患者在启动40mg瑞舒伐他汀治疗后出现肾小管毒性。文章指出,瑞舒伐他汀上市前临床试验显示高剂量下蛋白尿、血尿、横纹肌溶解及其他原因不明急性肾损伤发生率增加,部分病例有肾小管损伤证据。作者认为在接触强效他汀(如瑞舒伐他汀)尤其高剂量时出现不明原因肾损伤应考虑肾小管毒性,有限证据提示停药后肾脏预后良好。
要点
- 瑞舒伐他汀上市前临床试验显示高剂量下蛋白尿、血尿、横纹肌溶解及其他原因不明急性肾损伤发生率增加。
- 部分病例尿沉渣和肾组织学提示无横纹肌溶解的肾小管损伤。
- 接触强效他汀尤其高剂量时出现不明原因肾损伤应考虑肾小管毒性。
核心结论
- 在接触强效他汀(如瑞舒伐他汀)尤其高剂量时出现不明原因肾损伤,应考虑肾小管毒性。
- 有限证据提示此类病例停药后肾脏预后良好。
研究设计与样本
- 本文为病例报告,报告一例无既往肾脏疾病证据的患者在启动40mg瑞舒伐他汀治疗后出现肾小管毒性。
主要发现
- 瑞舒伐他汀上市前临床试验显示高剂量下蛋白尿、血尿、横纹肌溶解及其他原因不明急性肾损伤发生率增加。
- 上述原因不明急性肾损伤病例表现为尿沉渣异常,部分有肾组织学证据,提示无横纹肌溶解的肾小管损伤。
- 自瑞舒伐他汀广泛引入十余年来,文献中关于高剂量瑞舒伐他汀相关非横纹肌溶解介导的急性肾损伤报道极少,提示其或为罕见实体,或被系统性漏诊和漏报。
局限性
- 自瑞舒伐他汀广泛引入十余年来,文献中关于高剂量瑞舒伐他汀相关非横纹肌溶解介导的急性肾损伤报道极少,提示其或为罕见实体,或被系统性漏诊和漏报。
- 有限证据提示此类病例停药后肾脏预后良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preapproval clinical trials examining the safety and efficacy of rosuvastatin demonstrated an increased incidence of proteinuria, hematuria, rhabdomyolysis, and other acute kidney injury of unknown cause at high doses. The latter cases manifested with urine sediment findings and in some cases, renal histology, indicating renal tubular injury in the absence of rhabdomyolysis. Despite these provocative findings, there have been very few reports in the literature regarding non-rhabdomyolysis-mediated acute kidney injury associated with high-dose rosuvastatin since its widespread introduction more than a decade ago, suggesting that it is either a rare entity or systematically underdiagnosed and under-reported. We present a case of renal tubular toxicity attributable to the initiation of rosuvastatin treatment at a dose of 40mg in a patient with no prior evidence of kidney disease. Tubular toxicity should be considered in cases of unexplained kidney injury in the setting of exposure to a potent statin such as rosuvastatin, particularly at high dose. The limited evidence suggests a good kidney prognosis following withdrawal of the agent in these cases.
引用
- Ward FL, John R, Bargman JM, et al. Renal Tubular Toxicity Associated With Rosuvastatin Therapy. Am J Kidney Dis. 2016. PMID: 27856086. doi:10.1053/j.ajkd.2016.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。